Publicaciones en colaboración con investigadores/as de Fundación Hospital Alcorcón (15)

2024

  1. COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant

    Cancers, Vol. 16, Núm. 2

  2. Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)

    Scientific Reports

  3. Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases

    Microscopy and Microanalysis, Vol. 30, Núm. 1, pp. 151-159

2023

  1. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

2022

  1. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

    Scientific Reports, Vol. 12, Núm. 1

2020

  1. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study

    Journal of Hematology and Oncology, Vol. 13, Núm. 1

  2. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

    Blood Cancer Journal, Vol. 10, Núm. 10

2019

  1. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

    Haematologica, Vol. 104, Núm. 2, pp. 288-296

2018

  1. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

    PLoS ONE, Vol. 13, Núm. 9

2014

  1. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?

    Blood, Vol. 124, Núm. 12, pp. 1887-1893

2012

  1. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    Blood, Vol. 120, Núm. 13, pp. 2581-2588

2011

  1. Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: Toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03)

    Leukemia and Lymphoma, Vol. 52, Núm. 3, pp. 409-416

  2. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

    Blood, Vol. 118, Núm. 17, pp. 4547-4553

2010

  1. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial

    The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941

2009

  1. Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide

    Leukemia and Lymphoma, Vol. 50, Núm. 8, pp. 1283-1289